靶向肝细胞癌中细胞因子诱导的杀伤细胞与髓源性抑制细胞之间的相互作用
该研究探讨肝细胞癌中髓源性抑制细胞(MDSC)对细胞因子诱导的杀伤细胞(CIK)疗法的抑制机制。在两种小鼠肝细胞癌模型中,CIK细胞过继转移诱导肿瘤微环境中炎症介质产生并增加MDSC浸润,损害抗肿瘤活性;PDE5抑制剂他达拉非可逆转MDSC抑制功能并增强CIK疗效。
要点
- CIK细胞治疗可诱导肿瘤微环境中MDSC积聚,从而削弱其抗肿瘤活性。
- PDE5抑制剂他达拉非通过阻断ARG1和iNOS逆转MDSC的免疫抑制功能。
- 靶向MDSC可能是增强CIK细胞治疗肝细胞癌疗效的策略。
核心结论
- 研究结果提示,靶向MDSC是增强CIK细胞抗肿瘤疗效以治疗肝细胞癌患者的有效策略。
研究设计与样本
- 研究采用流式细胞术和定量实时PCR定量MDSC,细胞因子阵列检测细胞因子,体外乳酸脱氢酶细胞毒性实验评估CIK功能,并在C57BL/6和BALB/c小鼠中使用两种不同鼠源肝细胞癌细胞的皮下和原位肿瘤模型测试PDE5抑制剂他达拉非的体内外作用,同时体外测试人CIK和MDSC。
主要发现
- 在两种不同肝细胞癌模型中,CIK细胞过继转移至荷瘤小鼠后诱导肿瘤微环境中炎症介质(如CX3CL1、IL-13)产生并增加肿瘤浸润MDSC,导致抗肿瘤活性受损。
- 体外实验中MDSC有效抑制CIK的细胞毒活性。
- PDE5抑制剂治疗通过阻断ARG1和iNOS逆转MDSC的抑制功能,全身性PDE5抑制剂治疗在CIK细胞治疗后阻止肿瘤微环境中MDSC积聚并提高其抗肿瘤疗效。
- 在CD14+HLA-DR-/low MDSC存在下体外测试人CIK时观察到类似结果;PDE5抑制剂处理MDSC可抑制其抑制功能并增强CIK对人肝细胞癌细胞的体外活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cytokine-induced killer (CIK) cell-based immunotherapy is effective as an adjuvant therapy in early stage hepatocellular carcinoma (HCC) but lacks efficacy in advanced HCC. We aimed to investigate immune suppressor mechanisms in HCC, focusing on the role of myeloid-derived suppressor cells (MDSCs) in response to CIK therapy. METHODS: MDSCs were quantified by flow cytometry and quantitative real-time PCR. Cytokines were detected by cytokine array. A lactate dehydrogenase cytotoxicity assay was performed in the presence or absence of MDSCs to study CIK function against HCC cells in vitro. An FDA-approved PDE5 inhibitor, tadalafil, was used to target MDSCs in vitro and in vivo. Two different murine HCC cell lines were tested in subcutaneous and orthotopic tumor models in C57BL/6 and BALB/c mice. The antitumor effects of human CIKs and MDSCs were also tested in vitro. RESULTS: Adoptive cell transfer of CIKs into tumor-bearing mice induced inflammatory mediators (e.g., CX3CL1, IL-13) in the tumor microenvironment and an increase of tumor-infiltrating MDSCs, leading to impaired antitumor activity in 2 different HCC models. MDSCs efficiently suppressed the cytotoxic activity of CIKs in vitro. In contrast, treatment with a PDE5 inhibitor reversed the MDSC suppressor function via ARG1 and iNOS blockade and systemic treatment with a PDE5 inhibitor prevented MDSC accumulation in the tumor microenvironment upon CIK cell therapy and increased its antitumor efficacy. Similar results were observed when human CIKs were tested in vitro in the presence of CD14+HLA-DR-/low MDSCs. Treatment of MDSCs with a PDE5 inhibitor suppressed MDSC suppressor function and enhanced CIK activity against human HCC cell lines in vitro. CONCLUSION: Our results suggest that targeting MDSCs is an efficient strategy to enhance the antitumor efficacy of CIKs for the treatment of patients with HCC. LAY SUMMARY: Cytokine-induced killer cells are a mixture of immune cells given to eliminate cancer cells. However, not all patients respond to this treatment. Herein, we show in 2 different liver cancer models that myeloid-derived suppressor cells are increased in response to cytokine-induced killer cell therapy. Targeting these myeloid-derived suppressor cells may provide an additional therapeutic benefit alongside cytokine-induced killer cell therapy.
引用
- Yu SJ, Ma C, Heinrich B, et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J Hepatol. 2018. PMID: 30414862. doi:10.1016/j.jhep.2018.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。